Currently, clinical guidelines offer little guidance on deintensifying care, which is critical for balancing overuse and underuse of services.
Most healthcare services involve ongoing testing or treatment for chronic diseases. While clinical guidelines are useful to balance overuse and underuse, they need to be updated to specify when physicians should deintensify care, according to authors of a letter in JAMA Internal Medicine.
Adam A. Markovitz, BS, and colleagues at the VA Center for Clinical Management and Research in Ann Arbor, Michigan, examined current clinical guidelines for diabetes and cardiovascular disease in an attempt to understand the balance between overuse and underuse in current guidelines and whether guidelines recommend intensification more than deintensification.
Of the 361 recommendations identified, 71% were for intensification and only 29% were for deintensification. One example of intensification that the authors noted was from the American Diabetes Association Standards of Medical Care in Diabetes—2016, which recommended that people with diabetes and hypertension be treated to a systolic blood pressure goal of less than 140 mm Hg. An example of deintensification was the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes recommendation that there is potential harm in lowering systolic blood pressure to less than 120 mm Hg in older adults with type 2 diabetes.
The analysis also found that there was a large variation in how frequently guideline developers recommend deintensification.
The reason for so many more recommendation for intensification may be as simple as the fact that there is more evidence regarding intensification. Randomized clinical trials focus on evidence for initiating or intensifying treatment.
“The large variation detected across guideline developers underscores a second explanation—developers’ inconsistent engagement with existing evidence on benefit and harm,” the authors wrote.
When results from homogenous trial populations are generalized to the broader population, developers tend to provide “unqualified intensification recommendations,” while using vague statements to note deintensification recommendations.
Without deintensification trials, existing trials should document harms more reliably, the authors suggested. They added that guideline developers should better account for treatment heterogeneity.
“Given guidelines’ potential impact on clinical practice and performance measurement, appropriate attention to deintensification is critical,” the authors wrote.
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More